Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Crohns Disease Treatment Market

Crohns Disease Treatment Market Share

Report ID: GMI10038
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Crohn’s Disease Treatment Market Share

The Crohn’s disease treatment industry is characterized by intense competition among key players aiming to expand their market presence. Leading companies are focusing on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market position. These efforts are aimed at enhancing their product offerings, expanding their geographic reach, and investing in advanced technologies to strengthen their market presence.

Crohn’s Disease Treatment Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the Crohn’s disease treatment industry are as mentioned below:

AbbVie Inc.
Amgen Inc.
AstraZeneca Plc
Biogen
Boehringer Ingelheim GmbH
Bristol Myerr Squibb
Eli Lilly and Company
Janssen Pharmaceuticals (Johnson & Johnson)
Merck & Co. Inc
Novartis AG
Pfizer, Inc.
Salix Pharmaceuticals, Inc.
Takeda Pharmaceutical Industries Limited
Viatris Inc. (Mylan N.V.)

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Crohn’s disease treatment industry size was worth USD 13.3 billion in 2023 and will grow at a 4% CAGR between 2024 and 2032, driven by the rising prevalence of the Crohn’s disease globally.

The medication segment garnered USD 7.2 billion in 2023, primarily due to the increasing adoption of biologics and small molecule therapies, which offer improved efficacy and safety profiles.

North America Crohn’s disease treatment industry captured 44.2% in 2023, owing to the high prevalence of the disease, advanced healthcare infrastructure, and significant investment in research and development.

Prominent companies including AbbVie Inc., Amgen Inc., AstraZeneca Plc, Biogen, Boehringer Ingelheim GmbH, Bristol Myerr Squibb, Eli Lilly and Company, Janssen Pharmaceuticals (Johnson & Johnson), Merck & Co. Inc, Novartis AG, and Pfizer, Inc. are operating in the Crohn’s disease treatment industry.